Greenwich LifeSciences (GLSI) Proxy filing summary

Executive summary

• Annual meeting scheduled for December 18, 2026, at 9:00 a.m. local time in New York; October 26, 2026 is the record date, with 14,678,208 common shares outstanding.

• Stockholders will vote on five director nominees, auditor ratification, advisory executive compensation, and the frequency of future say-on-pay votes.

Voting matters and shareholder proposals

• Board recommends voting FOR all five director nominees, MaloneBailey LLP’s appointment, and advisory approval of executive compensation; it recommends say-on-pay votes every three years.

• Directors are elected by plurality for one-year terms through the 2027 annual meeting; other proposals require a majority of voting power present and entitled to vote.

• Uninstructed proxies are voted FOR the nominees, auditor ratification, say-on-pay, and three-year say-on-pay frequency; proxies may be revoked before being voted.

• Stockholder proposals for inclusion at the 2027 annual meeting are due June 30–July 30, 2027; alternate dates apply if the meeting shifts by specified amounts.

Board of directors and corporate governance

• Nominees are David B. McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, and Kenneth Hallock.

• CEO Snehal Patel and Board Chair David McWilliams are separate roles; the Board cites stronger management accountability and independent oversight as benefits.

• McWilliams, Rothe, and Hallock were determined independent under Nasdaq and SEC rules and served on the Audit and Compensation Committees as of December 31, 2025.

• During FY2025, the Board held four meetings, while the Audit and Compensation Committees each held one; no director attended fewer than 75% of applicable meetings.

• Director nomination criteria include experience, qualifications, time commitment, Board needs, and diversity; there are no term limits, and tenure is considered in reelection decisions.